The Phase III VALUE trial for EscharEx® is currently progressing, with an anticipated interim assessment and completion of enrollment by the end of the first quarter of 2027. This trial is a significant step in the development of EscharEx®, a potential medical treatment. Stay tuned for updates as we move closer to these important milestones.